Pipeline
Antabio portfolio
MEM-PIL
IV serine B-lactamase inhibitor combined with meropenemINDICATION
HABP/VABP, BSI
DEVELOPMENT STAGE
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PEi
Inhaled Pseudomonas aeruginosaelastase inhibitorINDICATION
Chronic Respiratory Diseases
DEVELOPMENT STAGE
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Novel Target / Novel Chemical Series
Three programs on novel targets / novel chemical seriesINDICATION
Oral/IV,
Nosocomial Infections
In collaboration with
DEVELOPMENT STAGE
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
Novel Target 2
Small moleculeINDICATION
Oral/IV,
Nosocomial Infections
DEVELOPMENT STAGE
DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3